JP2019513138A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513138A5
JP2019513138A5 JP2018550558A JP2018550558A JP2019513138A5 JP 2019513138 A5 JP2019513138 A5 JP 2019513138A5 JP 2018550558 A JP2018550558 A JP 2018550558A JP 2018550558 A JP2018550558 A JP 2018550558A JP 2019513138 A5 JP2019513138 A5 JP 2019513138A5
Authority
JP
Japan
Prior art keywords
concentration
potassium
phosphorus
mannitol
serum albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018550558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/024365 external-priority patent/WO2017172643A1/en
Publication of JP2019513138A publication Critical patent/JP2019513138A/ja
Publication of JP2019513138A5 publication Critical patent/JP2019513138A5/ja
Withdrawn legal-status Critical Current

Links

JP2018550558A 2016-03-31 2017-03-27 改良された製剤によりアルファウイルスを安定化するための組成物及び方法 Withdrawn JP2019513138A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316262P 2016-03-31 2016-03-31
US62/316,262 2016-03-31
PCT/US2017/024365 WO2017172643A1 (en) 2016-03-31 2017-03-27 Compositions and methods for stabilizing alphaviruses with improved formulations

Publications (2)

Publication Number Publication Date
JP2019513138A JP2019513138A (ja) 2019-05-23
JP2019513138A5 true JP2019513138A5 (enExample) 2020-07-09

Family

ID=58537071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018550558A Withdrawn JP2019513138A (ja) 2016-03-31 2017-03-27 改良された製剤によりアルファウイルスを安定化するための組成物及び方法

Country Status (19)

Country Link
US (2) US10632184B2 (enExample)
EP (1) EP3436063A1 (enExample)
JP (1) JP2019513138A (enExample)
KR (1) KR20180135912A (enExample)
CN (1) CN109069614A (enExample)
AU (1) AU2017241590A1 (enExample)
BR (1) BR112018069035A2 (enExample)
CA (1) CA3019529A1 (enExample)
CO (1) CO2018010357A2 (enExample)
CR (1) CR20180456A (enExample)
DO (1) DOP2018000211A (enExample)
EC (1) ECSP18081486A (enExample)
MX (1) MX2018011837A (enExample)
NI (1) NI201800096A (enExample)
PE (1) PE20190149A1 (enExample)
PH (1) PH12018502119A1 (enExample)
SG (1) SG11201808458QA (enExample)
SV (1) SV2018005747A (enExample)
WO (1) WO2017172643A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087188A1 (en) 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
WO2021028406A1 (en) * 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations
CA3149932A1 (en) * 2019-08-09 2021-02-18 Valneva Se Single shot chikungunya virus vaccine
PH12022550939A1 (en) * 2019-10-25 2024-02-12 Bavarian Nordic As Chikungunya virus-like particle vaccine and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
BRPI0716145B1 (pt) 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US10137186B2 (en) 2013-03-14 2018-11-27 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗

Similar Documents

Publication Publication Date Title
JP2010529999A5 (enExample)
JP2017535616A5 (enExample)
JP2015525762A5 (enExample)
JP2016513069A5 (enExample)
EA201791111A1 (ru) Пероральная регидратационанная композиция и способы
JP2011088913A5 (enExample)
NZ629261A (en) Pharmaceutical formulations of tnf-alpha antibodies
CY1124076T1 (el) Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος
JP2019504086A5 (enExample)
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
JP2013193968A5 (enExample)
BR112015022210A8 (pt) formulações de anticorpo
JP2012515221A5 (enExample)
EA201490804A1 (ru) Препараты этанерцепта, стабилизированные хлоридом натрия
JP2015134763A5 (enExample)
JP2014139241A5 (enExample)
JP2013508315A5 (enExample)
JP2015535237A5 (enExample)
JP2022511335A5 (enExample)
JP2013144697A5 (enExample)
EA201691807A1 (ru) Лиофилизированные составы, содержащие фактор ix
BR112015028824A2 (pt) composição de tensoativo concentrada
EA201790950A1 (ru) Способы и композиции, в частности, для лечения синдрома дефицита внимания
HRP20200196T1 (hr) Fiziološki balansirane injektabilne formulacije fosnetupitanta
JP2020517665A5 (enExample)